SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

This study is testing a three-drug combination — selinexor, bortezomib, and dexamethasone (SVRd) — for people newly diagnosed with multiple myeloma (a blood cancer) that has formed tumors outside the bone marrow, known as extramedullary disease. **You may be eligible if...** - You are between 18 and 75 years old - You have a new diagnosis of multiple myeloma with tumors outside the bone marrow confirmed by imaging or biopsy - Your blood counts are adequate - You do not have active infections - You are willing and able to follow the study schedule, and are using reliable contraception if applicable **You may NOT be eligible if...** - You have previously received treatment for multiple myeloma - You have serious heart, lung, liver, or kidney disease - You are pregnant or breastfeeding - You have active infections or recent bleeding - You have had a recent blood clot, stroke, or brain bleed in the past year Talk to your doctor to see if this trial is right for you.